ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Has A Problem With Nuplazid

It has become apparent that Acadia Pharmaceuticals Inc (NASDAQ:ACAD) needs a commercial partner for Nuplazid to maintain ACAD stock value long-term.

Posted in Healthcare & Biotech, Members, Mergers & Acquisitions | Tagged , | Leave a comment

Weekend Blitz: XPO Logistics (XPO), Under Armour (UA), Fannie Mae (FNMA) Stock & CLF Stock

Important stories and news related to XPO Logistics (XPO stock), Under Armour, Fannie Mae (FNMA stock), ACAD stock, and CLF stock.

Posted in Members, Weekend Blitz | Tagged , , , , , , , , , , | Leave a comment

ACADIA Pharmaceuticals (ACAD) Buyout: Why The AstraZeneca (AZN) Rumor Matters

A bidding war for Acadia Pharmaceuticals and Nuplazid is likely to ensue after buyout rumors last Friday. Great news for ACAD stock owners.

Posted in Editor's Pick, Healthcare & Biotech, Members, Mergers & Acquisitions | Tagged , , , , , | Leave a comment

Biotech Hunter: Acadia Pharma (ACAD), Vertex Pharma (VRTX), Alkermes (ALKS) & VRX Stock

Alkermes stock, VRX stock, Acadia Pharmaceuticals, and Vertex Pharmaceuticals were all discussed in our first Biotech Hunter.

Posted in Editor's Pick, Healthcare & Biotech, Members | Tagged , , , , , , , | Leave a comment

Celgene (CELG), Valeant (VRX), Acadia (ACAD), & Gilead Sciences (GILD) Outlook On Drug Pricing Concerns

How Donald Trump’s stance on drug prices will affect each of BNL Finance covered biotechs: CELG, VRX, ACAD, JAZZ, and GILD.

Posted in Healthcare & Biotech, Members, Stock Ratings, Timely Analysis | Tagged , , , , , , , , , | Leave a comment

Why Acadia Pharmaceuticals (ACAD) Will Get More Than $44 From Pfizer (PFE)

Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma

Posted in Healthcare & Biotech, Members, Mergers & Acquisitions | Tagged , , , , , , , , | 1 Comment

Acadia Pharmaceuticals Inc (ACAD) Outlook With Lewy Body Dementia & Off Label Nuplazid Use

Acadia Pharmaceuticals’ Nuplazid is reportedly seeing a rise in off label use, specifically With Lewy Body Dementia. That’s great news for ACAD stock.

Posted in BNL Reports, Healthcare & Biotech | Tagged , | 5 Comments